Promotion of PDT efficacy by a Bcl-2 antagonist.

Promotion of PDT efficacy by a Bcl-2 antagonist.

Item
http://www.wikidata.org/entity/Q36670682
Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines.Adventures in photodynamic therapy: 1976-2008.Photodynamic therapy of cancer: an updateEpidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cellsThe Bcl-2 antagonist HA14-1 forms a fluorescent albumin complex that can be mistaken for several oxidized ROS probes.A role for hydrogen peroxide in the pro-apoptotic effects of photodynamic therapy.Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy.MicroRNAs associated with the efficacy of photodynamic therapy in biliary tract cancer cell lines.Actin cytoskeleton reorganization correlates with cofilin nuclear expression and ultrastructural changes in cho aa8 cell line after apoptosis and mitotic catastrophe induction by doxorubicin.On the use of fluorescence probes for detecting reactive oxygen and nitrogen species associated with photodynamic therapy.
P2860

Promotion of PDT efficacy by a Bcl-2 antagonist.

Item
http://www.wikidata.org/entity/Q36670682
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Promotion of PDT efficacy by a Bcl-2 antagonist.
@ast
Promotion of PDT efficacy by a Bcl-2 antagonist.
@en
type
label
Promotion of PDT efficacy by a Bcl-2 antagonist.
@ast
Promotion of PDT efficacy by a Bcl-2 antagonist.
@en
prefLabel
Promotion of PDT efficacy by a Bcl-2 antagonist.
@ast
Promotion of PDT efficacy by a Bcl-2 antagonist.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Promotion of PDT efficacy by a Bcl-2 antagonist.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1751-1097.2007.00267.X
P433
P478
P577
P5875
P698
P932